Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-06-03
2004-11-30
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S113000, C546S112000, C514S299000
Reexamination Certificate
active
06825212
ABSTRACT:
BACKGROUND OF THE INVENTION
Serotonin (5-Hydroxytryptamine)(5-HT) receptors play a critical role in many physiological and behavioral functions in humans and animals. These functions are mediated through various 5-HT receptors distributed throughout the body. There are now approximately fifteen different human 5-HT receptor subtypes that have been cloned, many with well-defined roles in humans. One of the most recently identified 5-HT receptor subtypes is the 5-HT6 receptor, first cloned from rat tissue in 1993 (Monsma, F. J.; Shen, Y.; Ward, R. P.; Hamblin, M. W.
Molecular Pharmacology
1993, 43, 320-327) and subsequently from human tissue (Kohen, R.; Metcalf, M. A.; Khan, N.; Druck, T.; Huebner, K.; Sibley, D. R.
Journal of Neurochemistry
1996, 66, 47-56). The receptor is a G-protein coupled receptor (GPCR) positively coupled to adenylate cyclase (Ruat, M.; Traiffort, E.; Arrang, J-M.; Tardivel-Lacombe, L.; Diaz, L.; Leurs, R.; Schwartz, J-C.
Biochemical Biophysical Research Communications
1993, 193, 268-276). The receptor is found almost exclusively in the central nervous system (CNS) areas both in rat and in human. In situ hybridization studies of the 5-HT6 receptor in rat brain using mRNA indicate principal localization in the areas of 5-HT projection including striatum, nucleus accumbens, olfactory tubercle, and hippocampal formation (Ward, R. P.; Hamblin, M. W.; Lachowicz, J. E.; Hoffman, B. J.; Sibley, D. R.; Dorsa, D. M.
Neuroscience
1995, 64,1105-1111).
There are many potential therapeutic uses for 5-HT6 ligands in humans based on direct effects and on indications from available scientific studies. These studies include the localization of the receptor, the affinity of ligands with known in vivo activity, and various animal studies conducted so far.
One potential therapeutic use of modulators of 5-HT6 receptor function is in the enhancement of cognition and memory in human diseases such as Alzheimer's.
The high levels of receptor found in important structures in the forebrain, including the caudate/putamen, hippocampus, nucleus accumbens, and cortex suggest a role for the receptor in memory and cognition since these areas are known to play a vital role in memory (Gerard, C.; Martres, M.-P.; Lefevre, K.; Miquel, M. C.; Verge, D.; Lanfumey, R.; Doucet, E.; Hamon, M.; E I Mestikawy, S.
Brain Research,
1997, 746, 207-219). The ability of known 5-HT6 receptor ligands to enhance cholinergic transmission also supports the potential cognition use (Bentley, J. C.; Boursson, A.; Boess, F. G.; Kone, F. C.; Marsden, C. A.; Petit, N.; Sleight, A. J.
British Journal of Pharmacology,
1999, 126(7), 1537-1542). Studies have found that a known 5-HT6 selective antagonist significantly increased glutamate and aspartate levels in the frontal cortex without elevating levels of noradrenaline, dopamine, or 5-HT. This selective elevation of neurochemicals known to be involved in memory and cognition strongly suggests a role for 5-HT6 ligands in cognition (Dawson, L. A.; Nguyen, H. Q.; Li, P.
British Journal of Pharmacology,
2000, 130(1), 23-26). Animal studies of memory and learning with a known selective 5-HT6 antagonist found some positive effects (Rogers, D. C.; Hatcher, P. D.; Hagan, J. J.
Society of Neuroscience, Abstracts
2000, 26, 680).
A related potential therapeutic use for 5-HT6 ligands is the treatment of attention deficit disorders (ADD, also known as Attention Deficit Hyperactivity Disorder or ADHD) in both children and adults. Because 5-HT6 antagonists appear to enhance the activity of the nigrostriatal dopamine pathway and because ADHD has been linked to abnormalities in the caudate (Ernst, M; Zametkin, A. J.; Matochik, J. H.; Jons, P. A.; Cohen, R. M.
Journal of Neuroscience
1998, 18(15), 5901-5907), 5-HT6 antagonists may attenuate attention deficit disorders.
Early studies examining the affinity of various CNS ligands with known therapeutic utility or a strong structural resemblance to known drugs suggests a role for 5-HT6 ligands in the treatment of schizophrenia and depression. For example, clozapine (an effective clinical antipsychotic) has high affinity for the 5-HT6 receptor subtype. Also, several clinical antidepressants have high affinity for the receptor as well and act as antagonists at this site (Branchek, T. A.; Blackburn, T. P.
Annual Reviews in Pharmacology and Toxicology
2000, 40, 319-334).
Further, recent in vivo studies in rats indicate 5-HT6 modulators may be useful in the treatment of movement disorders including epilepsy (Stean, T.; Routledge, C.; Upton, N.
British Journal of Pharmacology
1999, 127 Proc. Supplement 131 P and Routledge, C.; Bromidge, S. M.; Moss, S. F.; Price, G. W.; Hirst, W.; Newman, H.; Riley, G.; Gager, T.; Stean, T.; Upton, N.; Clarke, S. E.; Brown, A. M.
British Journal of Pharmacology
2000, 130(7), 1606-1612).
Taken together, the above studies strongly suggest that compounds which are 5-HT6 receptor ligands may be useful for therapeutic indications including: the treatment of diseases associated with a deficit in memory, cognition, and learning such as Alzheimer's and attention deficit disorder; the treatment of personality disorders such as schizophrenia; the treatment of behavioral disorders, e.g., anxiety, depression and obsessive compulsive disorders; the treatment of motion or motor disorders such as Parkinson's disease and epilepsy; the treatment of diseases associated with neurodegeneration such as stroke and head trauma; or withdrawal from drug addiction including addiction to nicotine, alcohol, and other substances of abuse.
Therefore, it is an object of this invention to provide compounds which are useful as therapeutic agents in the treatment of a variety of central nervous system disorders related to or affected by the 5-HT6 receptor.
It is another object of this invention to provide therapeutic methods and pharmaceutical compositions useful for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
It is a feature of this invention that the compounds provided may also be used to further study and elucidate the 5-HT6 receptor.
These and other objects and features of the invention will become more apparent by the detailed description set forth hereinbelow.
SUMMARY OF THE INVENTION
The present invention provides a 1-(aminoalkyl)-3-sulfonylazaindole derivative of formula I
wherein
W is N or CR
7
;
X is N or CR
8
;
Y is N or CR
9
;
Z is N or CR
10
with the proviso that at least one and no more than two of W, X, Y and Z must be N;
n is an integer of 2, 3, 4 or 5;
R
1
is an optionally substituted C
1
-C
6
alkyl, C
3
-C
7
cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;
R
2
is H, halogen, or a C
1
-C
6
alkyl, C
1
-C
6
alkoxy, C
3
-C
7
cycloalkyl, aryl or heteroaryl group each optionally substituted;
R
3
and R
4
are each independently H or an optionally substituted C
1
-C
6
alkyl group;
R
5
and R
6
are each independently H or a C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, C
3
-C
7
cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted, or R
5
and R
6
may be taken together with the atom to which they are attached to form an optionally substituted 5- to 8-membered ring optionally containing an additional heteroatom selected from O, NR
11
or SO
m
;
R
7
, R
8
, R
9
and R
10
are independently H, halogen, CN, OCO
2
R
12
, CO
2
R,
13
, CONR
14
R,
15
, SO
p
R
16
, NR
17
R
18
, OR
19
, COR
20
, or a C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, C
3
-C
7
cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R
11
, R
12
, R
13
, R
16
, R
19
and R
20
are each independently H or a C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, C
3
-C
6
cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R
14
and R
15
are each independently H or an optionally substituted C
1
Antane Schuyler A.
Bernotas Ronald Charles
Lenicek Steven Edward
Aulakh Charanjit S.
Lences Barbara L.
Wyeth
LandOfFree
1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3358675